Background {#Sec1}
==========

Diabetic nephropathy (DN) is a serious micro vascular complication in patients with diabetes mellitus (DM), affecting approximately 40 % of patients with type 1 or type 2 DM \[[@CR1], [@CR2]\]. It is the predominant cause of chronic kidney disease and renal failure, and is closely associated with many micro vascular diseases, leading to financial and medicinal burdens \[[@CR3]\]. Continued hyperglycemia associated with DM is the major cause of kidney dysfunction with metabolic and hemodynamic disorders arising from oxidative stress and inflammation \[[@CR4]\].

During DN progression, progressive alterations developfrom hyperfiltration through micro albuminuria to macro albuminuria, and finally to renal failure \[[@CR5]\]. Renal structural changes are found in the nephrons, especially in the primary part of the glomerulus, including podocyte loss, glomerular basement membrane (GBM) thickening, endothelial cell dysfunction, and mesangial extracellular matrix (ECM) expansion, resulting in protein leakage into the urine \[[@CR6]\]. Pulmonary dysfunction \[[@CR7]\], hyperlipidemia and non-alcoholic fatty liver disease \[[@CR8]\], cardiovascular disease \[[@CR9]\], and even heart failure \[[@CR10]\] have been reported to be positively associated with DN progression. Therefore, synergistic therapies targeting multiple mediators of DN are required for effective therapeutic strategies \[[@CR4]\].

The experimental models used for studying Chinese medicines (CMs) in DN treatment are diverse. For in vivo studies, different doses of streptozotocin (STZ) are administered to mimic type 1 or type 2 DM. Examples of the CMs that have been investigated are *Glycyrrhizauralensis* (*gan*-*cao*), *Carumcarvi* (*zang*-*hui*-*xiang*), *Allium sativum* (*da*-*suan*), and *Mesonaprocumbens* (*xian*-*cao*) \[[@CR11]--[@CR14]\]. In addition, alloxan (ALX)-induced mice, db/db mice, KK-Ay mice, and Otsuka Long-Evans Tokushima Fatty (OLETF) rats have been reported for investigation of CMs in DN treatment \[[@CR15]--[@CR18]\]. Meanwhile, glomerular endothelial cells, mouse podocyte cells, renal proximal epithelial cells, murine hepatocytes, mouse mesangial cells, and human mesangial cells are used as in vitro models for anti-DN mechanism studies \[[@CR19]--[@CR27]\]. By applying these models, the majority of studies have reported that CMs such as *Acacia nilotica* pods (*jin*-*he*-*huan*) \[[@CR28]\], *Artemisia campestris* (*huang*-*ye*-*hao*) \[[@CR29]\], *Paeonialactiflora* (*shao*-*yao*) \[[@CR30]\], and *Schisandra chinensis* (*wu*-*wei*-*zi*) \[[@CR21], [@CR31]\] exhibited beneficial effects on all stages of experimental DN and may protect multiple organs. Grapevine leaf (*Vitis labrusca*) extract was reported to exert hepatoprotective, cardioprotective, and renoprotective effects \[[@CR32]\]. Moreover, CM preparations such as *Fufang Xueshuantong Capsule* (*fu*-*fang*-*xue*-*shuan*-*tong*-*jiao*-*nang*), *Zhengqing Recipe* (*zheng*-*qing*-*fang*), and *Danggui Buxue Tang* demonstrated benefits for DN patients \[[@CR33]--[@CR35]\]. Representative CMs for the treatment of DN at different stages of disease progression and their underlying mechanisms are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Natural course of diabetic nephropathy (DN) progression and Chinese medicine (CM) interventions in different stages. **a** In the early stage characterized by hyperfiltration and hypertrophy, CMs have therapeutic effects based on their anti-oxidant or anti-inflammatory activities. Representatives are *Panax quinquefolium*, *Asparagus racemosus*, *Rosa laevigata*, and *Piper auritum* \[[@CR5], [@CR42]--[@CR44]\]. **b** In the incipient DN stage characterized by microalbuminuria, CMs such as *Cornus officinalis*, *Abelmoschus manihot*, *Schisandrae chinensis*, and *Paeonia lactiflora* exhibit anti-microalbuminuric effects and may slow down the propagation of DN \[[@CR19], [@CR21], [@CR46], [@CR47]\]. The mechanisms involve protecting podocytes, and suppressing extracellular matrix (ECM) expansion and the endothelin-reactive oxidative species (ET-ROS) axis. As both the early and incipient stages of DN are at least partially reversible, CM interventions, which have superior effects based on their anti-oxidant, anti-inflammatory, and other renoprotective activities, are recommended as early as possible. **c** In the overt and end-stage renal disease (ESRD) stages of DN characterized by proteinuria and glomerulosclerosis, respectively, CM prescriptions, such as *Zhen*-*wu*-*tang* (ZWT; also called Shinbu-to in Japan) consisting of five herbs including Common Monkshood root, Poria, White Peony root, *Atractylodis rhizome*, and *Zingiberis rhizome*, have demonstrated optimal effects on ameliorating proteinuria by suppressing the hyperactivity of the renal renin--angiotensin system \[[@CR72]\]

This article aims to review the experimental evidence for the effectiveness of CMs in DN management, with emphasis on their underlying mechanisms, and to discuss the combined use of CM herbs and chemical drugs in DN treatment.

Search strategy and selection criteria {#Sec2}
--------------------------------------

We searched for the terms "traditional Chinese medicine", "holistic therapy", and "traditional Chinese medicine prescriptions (or formula)" in combination with "diabetic nephropathy" and "diabetes" in PubMed, Google Scholar, and Web of Science between 1990 and 2014. Manual searches of in-text references from the selected articles were further performed. Studies were included if in vivo models were used to investigate the nephroprotective effects and mechanisms of CMs. Unpublished reports, Letters to the Editor, and the studies that only used in vitro models or did not provide information about the duration of animal studies were excluded.

CMs in experimental DN management {#Sec3}
---------------------------------

### CMs intervention in the early stage of experimental DN {#Sec4}

The potential signaling pathways involved in DN pathogenesis regulated by CMs are shown in Fig. [2](#Fig2){ref-type="fig"}. The early stage of DN is characterized by hyperfunction and hypertrophy arising from oxidative stress and inflammation \[[@CR3], [@CR36], [@CR37]\]. Under chronic hyperglycemia, the extracellular glucose forms advanced glycation end-products (AGEs). Activation of receptor of advanced glycation end-products (RAGE) on the plasma membrane has been proposed to contribute predominantly to the overproduction of reactive oxidative species (ROS) \[[@CR38]\]. Meanwhile, the polyol pathway of glucose metabolism activated by the intracellular glucose further aggravates the oxidative stress. Other major sources of excess ROS were reported to be enhanced protein kinase C (PKC) activity caused by activation of the polyol pathway \[[@CR39]\] and mitochondrial ROS production in response to mitochondrial damage. As a consequence, nuclear factor (NF)-κB becomes activated, followed by stimulation of pro-inflammatory cytokines (e.g., interleukin \[IL\]-6), chemokines (e.g., monocyte chemoattractant protein \[MCP\]-1), adhesion molecules (e.g., intercellular adhesion molecule 1 \[ICAM1\], vascular cell adhesion protein 1 \[VCAM1\]), and nuclear receptors (e.g., peroxisome proliferator-activated receptor \[PPARs\]) \[[@CR40]\]. Thereafter, the inflammation induces endoplasmic reticulum (ER) stress via unfolded protein response pathways, resulting in metabolic disorders and apoptosis. Besides, subsequent macrophage infiltration into renal tissues leads to prolonged micro inflammation, thus aggravating the progression of DN. Numerous CMs are applied at this point to control this reversible stage of DN \[[@CR41]\]. *Asparagus racemosus* (*lu*-*sun*), *Radix Astragali* (*huang*-*qi*), *Rosa laevigata* (*jin*-*ying*-*zi*), and *Piper auritum* (*hu*-*jiao*) were reported to enhance the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), leading to attenuation of the oxidative stress \[[@CR5], [@CR42]--[@CR44]\].Fig. 2Potential signaling pathways involved in diabetic nephropathy (DN) pathogenesis. Activation of receptor of advanced glycation end-products (RAGE) by advanced glycation end-products (AGEs) results in reactive oxidative species (ROS) overproduction, leading to oxidative stress. Meanwhile, the polyol pathway activated by intracellular glucose further aggravates the oxidative stress. Activation of protein kinase C (PKC) via the polyol pathway is another major source of ROS production. Mitochondrial damage also contributes to ROS production. ROS overproduction and impaired anti-oxidant response cause oxidative stress, which activates nuclear factor (NF)-κB and upregulates monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β. Thereafter, the inflammation induces endoplasmic reticulum (ER) stress via unfolded protein response pathways, resulting in metabolic disorders and apoptosis

### CMs intervention in the incipient stage of experimental DN {#Sec5}

The development of micro albuminuria was reported as an indicator of the incipient stage of DN, arising from endothelial dysfunction \[[@CR38], [@CR45]\]. Renal hypertrophy and hyperfiltration induced functional and structural alterations, resulting in micro albuminuria and hypertension, leading to glomerulus sclerosis, and progressing to incipient DN. *Cornus officinalis* (*shan*-*zhu*-*yu*), *Abelmoschus manihot* (*huang*-*shu*-*kui*), *Schisandrae chinensis* (*wu*-*wei*-*zi*), *and Paeonia lactiflora* (*shao*-*yao*) were reported to exhibit anti-micro albuminuria effects, thereby slowing down DN progression \[[@CR19], [@CR21], [@CR46], [@CR47]\].

### CMs intervention in the overt and end-stage renal disease (ESRD) stages of experimental DN {#Sec6}

After the incipient stage of DN and under hyperglycemic conditions, mesangial nodules and tubule interstitial fibrosis develop, leading to proteinuria and nephrotic syndrome, and eventually to the overt stage of DN, which is characterized by persistent proteinuria \[[@CR6]\]. Without effective control, patients in this stage will deteriorate to ESRD with uremia. As the kidney disease progresses, physical changes in the kidneys often lead to increased blood pressure and cardiovascular disease. In this stage, angiotensin-converting enzyme (ACE) inhibition is the conventional intervention \[[@CR48]\]. The goal of treatment is to prevent the progression from micro albuminuria to macro albuminuria, and multiple and more intensive strategies are strongly advised. Avosentan was reported to reduce albuminuria in patients with type 2 DM and overt nephropathy by inhibiting ACE and blocking angiotensin receptors, but can also induce significant fluid overload and congestive heart failure \[[@CR49]\]. *Averrhoa carambola* L. (*yang*-*tao*), *Salvia miltiorrhiza* (*dan*-*shen*), and *Picrorrhiza Rhizoma* (*hu*-*huang*-*lian*) can ameliorate DN symptoms safely \[[@CR50]--[@CR52]\]. Representative CMs and their related mechanisms are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Chinese medicines used in the management of experimental diabetic nephropathySpeciesMedicinal partExtract/CompoundDN modelNephro-protective MechanismsPharmacodynamic indicatorsDurationRef.*Eclipta alba* (*han*-*lian*-*cao*)--Ethanol extractSTZ rat↓α-glucosidase and aldose reductase activitiesFBG, HbA1C, urea, uric acid, UCr, insulin3 weeks\[[@CR76]\]*Gymnemamontanum*Hook (*shi*-*geng*-*teng*)--Ethanol extractALX rat↓TBARS, hydroperoxides; ↑SOD, CAT, GSH-Px, GSTFBG, insulin, urea, Cr, uric acid3 weeks\[[@CR77]\]*Cinnamomumzeylanicum* (*xi*-*lan*-*rou*-*gui*)--Aqueous extractSTZ rat↑UCP-1, GLUT4FBG, K/B ratio, insulin, HDL, TC, TG, Cr, histopathology22 days\[[@CR78]\]*Panaxnotoginseng* (*san*-*qi*)RootsNotoginosideSTZ rat↓VEGF; ↑BMP-7Cr, CCr, Ualb4 weeks\[[@CR79]\]*Mesonaprocumbens*Hemsl (*xiancao*)--Aqueous extractSTZ rat↓TSP-1Body weight, FBG, histopathology4 weeks\[[@CR14]\]*Piper auritum* (*hu*-*jiao*)LeavesHexane extractSTZ rat↓AGEs, serum glycosylated protein, LDL glycation, glycation hemoglobin, renal glucose, thiobarbituric acid-reactive substance; ↑SOD, CAT, GPx and GSHKidney oxidative stress4 weeks\[[@CR44]\]*Smallanthussonchifolius* (*xue*-*lian*)LeavesAqueous extractSTZ rat↓TGF-β1, Smad2/3, collagen III, collagen IV, laminin-1, FNFBG, insulin, UAE, Cr, kidney hypertrophy, GBM thickening4 weeks\[[@CR80]\]*Milk thistle* (*nai*-*ji*-*cao*)--SilymarinSTZ rat↓Lipid peroxidation; ↑CAT, SOD, GPxFBG, serum urea, Cr, Ualb4 weeks\[[@CR81]\]----CurcuminSTZ rat↓eNOS, ET-1, TGF-β1, FN, NF-κB, p300ECM4 weeks\[[@CR82]\]*Allium sativum*L. (*da*-*suan*)----STZ rat↓TBARS; ↑GSHFBG, insulin, TG, TC, CCr, UAE, NAG30 days\[[@CR13]\]*Psidiumguajava*L. (*fan*-*shi*-*liu*)LeavesTotal triterpenoidsHFD + STZ rat↓HyperglycemiaFBG, insulin, Cr, BUN, capillary, base-membrane incrassation, glomerular swelling, cysts and tubules edema6 weeks\[[@CR83]\]*Panaxnotoginseng* (*san*-*qi*)RootsNotoginosideSTZ rat↓TGF-β1; ↑Smad7FBG, renal index, CCr, UAlb6 weeks\[[@CR84]\]*Trigonellafoenumgraecum*(*xiang*-*cao*)SeedsAqueous extractHFD + STZ rat↓MDA, 8-hydroxy-2′-deoxyguanosine, renal cortex DNA; ↑SOD, CATFBG, K/B ratio, Cr, BUN, UAlb, and CCr, GBM6 weeks\[[@CR85]\]*Schisandraechinensis* (*wu*-*wei*-*zi*)FruitsEthanol extractSTZ mice↓EMT, α-SMA, PAI-1, E-cadherin, Snail; ↑E-cadherin, α-SMAACR, UAE, ECM deposition, podocyte loss and integrity of the slit diaphragm7 weeks\[[@CR21]\]----CurcuminSTZ mice↓COX-2, caspase-3, F- to G-actin cleavage; ↑p38-MAPK, HSP25UAlb, ACR7 weeks\[[@CR24]\]*Panax ginseng* (*ren*-*shen*)--ginsenoside 20(S)-Rg(3)OLETF rats↓TBARS, iNOS, CMLFBG, CCr, UAE, urine volume50 days\[[@CR18]\]*Polygonummultiflorum*Thunb (*he*-*shou*-*wu*)--TetrahydroxystilbeneSTZ rat↓TGF-β1, COX-2; ↑CAT, SOD, GSH-Px, SIRT1TC, TG, BUN, Cr, UAlb, K/B ratio, MDA8 weeks\[[@CR25]\]*Paeonialactiflora*Pall. (*shao*-*yao*)--Total glucosidesSTZ rat↓Macrophages accumulation and proliferation; ↑p-JAK2, p-STAT3UAlb8 weeks\[[@CR47]\]*Aceranthussagittatus* (*yin*-*yang*-*huo*)--IcariinSTZ rat↓MDA, Hyp, TGF-β1, collagen IV; ↑SODFBG, Cr, BUN, histopathology8 weeks\[[@CR86]\]*Angelica acutiloba* (*dang*-*gui*)RootsAqueous ethanol extractSTZ rat↓NF-κB, TGF-β1, FN, AGEs, RAGEFBG, UAlb, UAE, CCr, ECM expansion8 weeks\[[@CR87]\]*Salvia miltiorrhiza* (*dan*-*shen*)--Aqueous extractSTZ rat↓TGF-β1, AGEs, RAGE, collagen IV and ED-1FBG, UAlb, UAE8 weeks\[[@CR51]\]*Tripterygium wilfordii* (*lei*-*gong*-*teng*)--Multi-glycosideSTZ rat↓Mesangial cell proliferation, α-SMA, collagen 1Body weight, UAlb, FBG, Cr, BUN, histopathology8 weeks\[[@CR88]\]*Hibiscus sabdariffa* L (*luo*-*shen*-*hua*)FlowersPolyphenolsSTZ rat↓TBARS; ↑CAT and GSHK/B ratio, proximal convoluted tubules, TG, TC, LDL8 weeks\[[@CR89]\]*Panaxquinquefolium* (*xi*-*yang*-*shen*)RootsEthanol extractSTZ+ db/db mice↓Oxidative stress, NF-κB p65, ECM, vasoactive factorsAlbuminuria and mesangial expansion6 and 8 weeks\[[@CR90]\]*Rheum officinale* (*da*-*huang*)--Rheindb/db mice↓TGF-β1, FNUAE, ECM, TC, TG, LDL-C, Apo E8 weeks\[[@CR91]\]*Averrhoa carambola* L (*yang*-*tao*)Roots2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dioneKKAy mice↓Hyperglycemia, AGE, NF-κB, TGF-β1, CML; ↑SOD and GSH-Px activitiesProteinuria, Cr, CCr, serum urea-N, ECM expansion8 weeks\[[@CR17]\]*Radix Astragali* (*huang*-*qi*)RootsAqueous extractSTZ rat↓MDA, IL-6, TNF-α, NF-κB, PKCα; ↑SOD and GSH-Px activitiesFBG, body weight, Cr60 days\[[@CR42]\]*Glycyrrhizauralensis* (*gan*-*cao*)----STZ rat↓MDA; ↑GSH, SOD and CATFBG, body weight, histopathology60 days\[[@CR11]\]*Acacia nilotica* (*jin*-*he*-*huan*)PodsAqueous methanol extractSTZ rat↓Hyperglycemia, LPO, ↑SOD and GSH activitiesFBG, serum urea, Cr, histopathology60 days\[[@CR28]\]*Portulacaoleracea* (*ma*-*chi*-*xian*)--Aqueous extractdb/db mice↓TGF-β1, AGEs, ICAM-1, NF-κB p65FBG, Cr, water intake and urine volume10 weeks\[[@CR92]\]----GenisteinSTZ mice↓ICAM-1, gp91 and TBARs; ↑ phospho-tyrosine and phospho-ERK/ERK ratioFBG, insulin, total protein, UAlb, urinary MCP-1 excretion10 weeks\[[@CR93]\]*Smilax glabra*Roxb (*tu*-*fu*-*ling*)RhizomeAstilbinSTZ rat↓TGF-β1, CTGFBody weight, survival time, FBS6 and 12 weeks\[[@CR94]\]*Psidiumguajava*L. (*fan*-*shi*-*liu*)FruitsAqueous + methanol extractSTZ mice↓AR activity, ROS, IL-6, TNF-α, IL-1β, CML, MDA, AR and AGEs; ↑GSH, CAT, GSH-PxBody weight, insulin12 weeks\[[@CR95]\]----Caffeic acid, ellagic acidSTZ mice↓Sorbitol dehydrogenase, AR, IL-1, IL-6, TNF-α, MCP-1Body weight, urine volume, insulin, FBG, BUN, CCr, HbA1c, UAlb12 weeks\[[@CR96]\]*Trigonellafoenumgraecum*L. (*hu*-*lu*-*ba*)SeedsSeed powderALX rat↓Glucose, urea, creatinine, sodium, potassium and IL-6 in serum, MDA and IL-6 in kidney; ↑SOD and CAT activities, GSHGlomerular mesangial expansion12 weeks\[[@CR97]\]*Cornus officinalis* (*shan*-*zhu*-*yu*)Fruits--HFD + STZ rat↓FBG, NAG, mALB; ↑insulin and Wilms tumor 1 in glomeruliFBG, mALB, UCr, BUN, NAG, histopathology12 weeks\[[@CR19]\]*Euonymus alatus* (*wei*-*mao*)Leaves and branchesAqueous extractUninephrectomy + STZ rat↓TGF-β1Blood lipids, UAlb, HbA1c, ECM expansion and glomerulus sclerosis12 weeks\[[@CR98]\]*Aster koraiensis* (*zi*-*yuan*)Aerial partEthanol extractSTZ rat↓AGEs accumulation, Bax; ↑Bcl-2FBG, HbA1c, UAE, histopathology13 weeks\[[@CR99]\]*Rosa laevigata*Michx. (*jin*-*ying*-*zi*)FruitsAqueous extractSTZ rat↓MDA, ROS, NF-κB p65, MCP-1;↑SOD and antioxidant activities, IκBαKidney oxidative stress24 weeks\[[@CR43]\]*Abelmoschusmanihot*L. (*huang*-*shu*-*kui*)FlowersTotal flavone glycosides, hyperosideSTZ rat↓Glomerular cell and podocytes apoptosis, caspase-3, caspase-8ACR, UAlb24 weeks\[[@CR46]\]*AGEs* advanced glycation end products, *ALX* alloxan, *AR* aldose reductase, *ACR* urinary microalbumin to creatinine ratio, *BMP* bone morphogenetic protein, *BUN* blood urea nitrogen, *CAT* catalase, *CCr* creatinine clearance rate, *CML* N(epsilon)-(carboxymethyl) lysine, *CTGF* connective tissue growth factor, *COX* cyclooxygenase, *ECM* extracellular matrix, *ED-1* monocyte/macrophage, *ET-1* endothelin-1, *EMT* epithelial-to-mesenchymal transition, *ERK* extracellular signal-regulated kinases, *FBG* fasting blood glucose, *FN* fibronectin, *GBM* glomerular basement membrane, *GLUT* glucose transporter, *GSH-Px* glutathione peroxidase, *GST* glutathione-S-transferase, *HFD* high fat diet, *HDL* high density lipoprotein, *HSP* heat shock protein, *Hyp* hydroxyproline, *ICAM* intercellular adhesion molecule, *JAK* janus kinase, *K/B* kidney/body weight, *LDL* low density lipoprotein, *LPO* lipid peroxidation, *iNOS* inducible nitric oxide synthase, *eNOS* endothelial nitric oxide synthase, *NAG* N-acetyl-beta-D-glucosaminidase, *NF-κB* nuclear factor κB, *MAPK* mitogen-activated protein kinase, *mALB* microalbuminuria, *MCP* monocyte chemotactic protein, *MDA* malondialdehyde, *PAI* plasminogen activator inhibitor, *ROS* reactive oxidative species, *RAGE* receptor of advanced glycation end-products, *STAT3* signal transducer and activator of transcription 3, *α-SMA* α-smooth muscle actin, *STZ* Streptozotocin, *SIRT1* Sirtuin 1, *SOD* superoxide dismutase, *TARS* thiobarbituric acid reactive substances, *TGF* transforming growth factor, *TG* triglyceride, *TC* total cholesterol, *TSP-1* thrombospondin-1, *UAlb* urinary microalbumin, *UAE* urinary albumin excretion, *UCr* urinary creatinine, *UCP* uncoupling protein, *VEGF* vascular endothelial growth factor

Besides targeting the specific molecules involved in DN pathogenesis to exert anti-hyperglycemic and nephroprotective effects, CM has unique characteristics in DN management. In CM, DN is not only a kidney disease, but also an embodiment of the systemic disease in the kidney, which is in accordance with the latest findings for DN pathogenesis \[[@CR7], [@CR8], [@CR38]\]. The pathogenesis of DN may be closely related to the dysfunction or impairment of other organs, and therefore treatments for diseases in other organs may be helpful for the amelioration of DN, especially in the overt and ESRD stages. The normal functioning of the human body relies on the coordination of *yin*and *yang*, and the five *zang* organs (*wuzang*), i.e., the *liver* (*gan*), *heart* (*xin*), *spleen* (*pi*), *lung* (*fei*), and *kidney* (*shen*), are respectively related to *wood* (*mu*), *fire* (*huo*), *earth* (*tu*), *metal* (*jin*), and *water* (*shui*) and connected under the laws of inter promotion and interaction (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR53]\]. Once a significant imbalance occurs, certain symptoms of the kidneys inevitably and predictably arise.Fig. 3Schematic diagram integrating the Chinese medicine (CM) view on the holistic therapy and modern pathogenesis concepts of diabetic nephropathy (DN). The core shows the holistic view of DN under CM theory, which is based on the *Yin*-*Yang* and *Five Elements* theories. The regular functioning of the human body relies on the coordination of *Yin* and *Yang* in a unity of opposites, and the liver, heart, spleen, lung, and kidneys are respectively related to *wood*, *fire*, *earth*, *metal*, and *water* \[[@CR53]\]. In particular, the spleen in CM is a functional organ that governs transport and transformation in a close relationship with the stomach and pancreas \[[@CR73]--[@CR75]\]. This theory reflects the unification and integration together with the impact caused by the breakdown of the balance as a consequence of overacting and counteracting relationships, which is of practical significance in CM clinical practice. The peripheral annotations imply recent therapeutic strategies against DN specific to individual organs. The *solid arrows* denote interpromoting relationships. The *dashed arrows* indicate interacting/counteracting relationships

Under hyperglycemic conditions, the oxidative stress and inflammation affect the blood circulatory system, consequently leading to the dysfunction of multiple organs. Cardiovascular disease causes even more deaths than ESRD in patients with DN \[[@CR38]\]. The degree of pulmonary function impairment was found to be positively associated with the stage of DN progression \[[@CR7]\]. Besides, liver X receptor (LXR) agonists, which are commonly used to treat hyperlipidemia and non-alcoholic fatty liver disease, were shown to ameliorate DN by inhibiting the expressions of osteopontin and other inflammatory mediators in the kidney cortex \[[@CR8]\]. Moreover, during DN pathogenesis, glomerular hypertrophy was found to be associated with hyperinsulinemia \[[@CR54]\], and has been proposed as a novel therapeutic target for DN \[[@CR55]\]. As a systematic micro vascular thrombosis combined with metabolic disorders, DN influences the whole internal environment, and its pathogenesis may be closely related to the dysfunction of other organs.

From this perspective, CM as a therapeutic approach targeting multiple organs is preferred to improve the overall health of DN patients. Experimentally, grapevine (*Vitis labrusca* L.) leaves exhibited hepatoprotective, cardioprotective, and renoprotective effects in Wistar rats \[[@CR32]\]. Besides, extracts from *S. miltiorrhiza* exhibited a regulatory effect on the expression of LXR-α in hyperlipidemic rats \[[@CR56]\]. Furthermore, *Liuwei Dihuang* Decoction exhibited a protective effect on early DN in STZ rats \[[@CR57]\]. Additionally, a CM prescription, *kangen*-*karyu*, exhibited hepatoprotective/renoprotective activities through the inhibition of AGE formation and fibrosis-related protein expressions in type 2 diabetes \[[@CR58]\]. Yamabe and colleagues systematically conducted a series of experiments to investigate the anti-diabetic effects of a CM prescription, *hachimi*-*jio*-*ga*, and reported findings for the whole prescription and its constituents as well as for the bioactive compound \[[@CR59]--[@CR64]\]. Other selected CM prescriptions for DN treatments and their respective molecular mechanisms are shown in Table [2](#Tab2){ref-type="table"}. In particular, single herbs (e.g., *Auricularia auricula*, *hei*-*mu*-*er*) and CM prescriptions (e.g., *Danggui Buxue Tang* and *Gui Qi Mixture*) produced better beneficial effects than conventional anti-DN drugs by regulating blood lipid metabolism and lipoprotein lipase activity through the regulation of blood glucose based on their complex compound matrices \[[@CR65]--[@CR67]\]. The changes in blood glucose, triglyceride (TG), total cholesterol (TC), and high-density lipoprotein (HDL) were reversed by *Gui QiMixture*, but not by the ACE inhibitor benazepril in diabetic rats \[[@CR68]\]. Similarly, the increases in fasting blood glucose (FBG), TG, and TC were attenuated, and the renal kidney/body weight (K/B) ratio, urinary albumin excretion (UAE), and creatinine clearance rate (CCr) in STZ-induced diabetic rats were ameliorated after 8 weeks of treatment with *Danggui Buxue Tang* compared with benazepril \[[@CR69]\]. Collectively, CMs may exert synergetic effects targeting multiple organs, and benefiting the whole internal milieu of DN patients.Table 2Experimental studies on selected CM prescriptions in diabetes nephropathy managementCM preparationsDN modelNephro-protective mechanismsPharmacodynamic indicatorsDosageDurationRef.*Xiao*-*chai*-*hu*-*tang*STZ rat↓TGF-β1, FN, and collagen IV,↑BMP-7, SODFBG, BUN, SCr, renal hypertrophy200 mg/kg b.w4 weeks\[[@CR100]\]*LiuweiDihuang Decoction*STZ rat↓MDA, iNOS, tNOS, cNOS, ET-1, ET(A), ↑NO, MMP-2, MMP-9, GSH-Px, SODFBG, plasma insulin level5, 10, or 15 g/kg b.w4 weeks\[[@CR57]\]*Tangshenling mixture plus benazepril*STZ rat↓ANF, GLUT1UAE, CCr, K/B ratio5 g/kg b.w6 weeks\[[@CR71]\]*DangguiBuxue Tang*STZ rat↓TGF-β1K/B ratio, UAE, β(2)-MG concentrations, CCr, FBG, TC, TG--8 weeks\[[@CR69]\]*Dang*-*gui and Huang*-*qi mixture*STZ rat↓TGF-β1, Ang IIFBG, TG, CHO, HDL, SCr, CCr, BUN, β(2)-MG,K/B ratio, GA--8 weeks\[[@CR68]\]*Tangshenning Recipe*STZ rat↓TXB(2), TXB(2)/6-keto-PGF1 α, CGRP, MDA; ↑ET, SOD, GSH--35 g/kg b.w8 weeks\[[@CR101]\]*Shenbao Recipe*STZ rat↓CTGF, ↑MMP-9UAlb, FBG, TC, SCr13 g/kg b.w8 weeks\[[@CR102]\]*Wu*-*ling*-*san*STZ rat↓NF-κB, TGF-β1, FN, AGEs, mitochondrial TBARS, CMLUAE, UAlb, CCr, mesangial matrix expansion2.5 g/kg b.w10 weeks\[[@CR103]\]*Zhen*-*wu*-*tang*STZ rat↓Ang II, ↑nephrin, podocinBody weight, polyurea, UAE, SCr, BUN320 mg/kg b.w.12 weeks\[[@CR72]\]*FufangXueshuantong Capsule*HFD + STZ rat↑GSH-px, SODUAE, CCr, masengial matrix expansion450, 900, or 1800 mg/kg b.w12 weeks\[[@CR104]\]*Hachimi*-*jio*-*gan*STZ rat↓AGEs, sorbitolFBG, UAE, CCr, serum glycosylated protein, BUN, serum albumin level, TG, TC50,100, or 200 mg/kg b.w15 weeks\[[@CR59]\]*Kangen*-*karyu*STZ mouse↓AGEs, TGF-β1, collagen IVFBG, BUN100, 200 mg/kg b.w18 weeks\[[@CR58]\]*Hachimi*-*jio*-*gan*OLETF rats↓NF-κB, TGF-β1, FN, iNOS, cyclooxygenase-2, AGEs, TBARSUAE, CCr, FBG50, 100, or 200 mg/kg b.w32 weeks\[[@CR61]\]*Yiqiyangyinhuayutongluo recipe*HFD + STZ rat↑NephrinFBG, UAE, 24 h U-nephrin0.8 g/kg b.w32 weeks\[[@CR105]\]*AGEs* advanced glycation end products, *ANF* atrial natriuretic factor, *Ang II* angiotensin II, *BMP* bone morphogenetic protein, *BUN* blood urea nitrogen, *CCr* creatinine clearance rate, *CHO* cholesterol, *CML* N(epsilon)-(carboxymethyl)lysine, *CGRP* calcitonin gene-related peptide, *CTGF* connective tissue growth factor, *ET* endothelin, *FBG* fasting blood glucose, *GA* glomerular area, *GLUT* glucose transporter, *TGF* transforming growth factor, *FN* fibronectin, *GSH-Px* glutathione peroxidase, *HDL* high density lipoprotein, *HFD* high fat diet, *K/B* kidney/body weight, *NF-κB* nuclear factor κB, *NO* nitric oxide, *cNOS* constitutive nitric oxide synthase, *eNOS* endothelial nitric oxide synthase, *iNOS* inducible nitric oxide synthase, *nNOS* constitutive nitric oxide synthase, *tNOS* total nitric oxide synthase, *MDA* malondialdehyde, *MMP* matrix metalloproteinase, *β (2)-MG* Urine β (2)-microglobin, *OLETF* otsuka long-Evans Tokushima Fatty, *PGF* prostaglandin F, *SCr* serum creatinine clearance rate, *STZ* streptozotocin, *SOD* superoxide dismutase, *TGF* transforming growth factor, *TG* triglyceride, *TC* total cholesterol, *TARS* thiobarbituric acid reactive substances, *TXB(2)* thromboxane B 2, *UAE* urinary albumin excretion rate, *UAlb* urinary microalbumin

At the ESRD stage, it is almost impossible to prevent the disease from becoming more severe, and dialysis may be the final resort for these patients. To provide a more cost-effective therapeutic approach, other potent remedies are urgently needed. In this regard, the combined use of herbs and drugs, and the development of new therapies are receiving increasing attention.

Modern drugs specifically aim to target disease-related molecules through definite pathways, whereas CM aims to exert synergetic effects and benefit the whole internal milieu of patients, leading to the possibility that the combined use of CMs and modern drugs may exert better therapeutic effects on diseases, especially for chronic and comprehensive DN. Currently, the combined use of herbs and drugs in the treatment of DN has been well-investigated. For example, the CM prescription *tangshenling* was combined with telmisartan to treat 80 patients with DN, and exhibited a better effect than telmisartan treatment alone \[[@CR70]\]. Basic research corroborated that the *tangshenling* mixture had a synergetic effect with benazepril through a different signaling pathway, which involved down regulation of atrial natriuretic factor (ANF) in plasma and glucose transporter 1 (GLUT1) in the kidney when treating DN \[[@CR71]\]. Herbs may reduce the permeability of the drug into the intestinal tract, and may also affect its metabolism in the liver and cause hypoglycemia. *Huang Kui* capsule reduced the absorption of glibenclamide and accelerated its metabolism. This herb--drug interaction deserves further research on the herb--drug pharmacokinetic interaction to enhance the therapeutic effects and avoid side effects.

Limitations of this review {#Sec7}
==========================

In many studies included in this review, the bioactivities of the CMs responsible for the anti-DN effects and their molecular targets were not identified. Phytochemical and molecular biological studies are needed to identify the bioactive constituents and to elucidate the underlying mechanisms. Moreover, this review only focused on studies using in vitro or in vivo DN models. Results from clinical trials investigating the use of CMs for the treatment of DN are needed to confirm the therapeutic effects of CMs in the future.

Conclusion {#Sec8}
==========

CMs provides an alternative for DN management in all stages of experimental DN models, especially in the early and incipient stages of DN, and the synergistic administration of CM herbs with conventional drugs exhibited better efficacy than drugs alone in DN treatment.

ANF

:   atrial natriuretic factor

AGEs

:   advanced glycation end products

Ang II

:   angiotensin II

ALX

:   alloxan

AR

:   aldose reductase

ACE

:   angiotensin-converting enzyme

ARB

:   angiotensin receptor blocker

ACR

:   urinary microalbumin to creatinine ratio

BUN

:   blood urea nitrogen

BMP

:   bone morphogenetic protein

CAT

:   catalase

CCr

:   creatinine clearance rate

CGRP

:   calcitonin gene-related peptide

CHO

:   cholesterol

CTGF

:   connective tissue growth factor

CML

:   n(epsilon)-(carboxymethyl)lysine

DM

:   diabetes mellitus

DN

:   diabetic nephropathy

ER

:   endoplasmic reticulum

ET-1

:   endothelin-1

ESRD

:   end-stage renal disease

EMT

:   epithelial-to-mesenchymal transition

ECM

:   extracellular matrix

EMMPRIN

:   extracellular matrix metalloproteinase inducer

ERK

:   extracellular signal-regulated kinases

ED-1

:   monocyte/macrophage

FBG

:   fasting blood glucose

FN

:   fibronectin

GA

:   glomerular area

GFR

:   glomerular filtration rate

GMCs

:   glomerular mesangial cells

GBM

:   glomerular basement membrane

GSH-Px

:   glutathione peroxidase

GST

:   glutathione-S-transferase

GLUT

:   glucose transporter

HDL

:   high density lipoprotein

HFD

:   high fat diet

Hyp

:   hydroxyproline

iNOS

:   inducible nitric oxide synthase

ICAM

:   intercellular adhesion molecule

IGF

:   insulin-like growth factor

K/B

:   kidney/body weight

LPO

:   lipid peroxidation

LPL

:   lipoprotein lipase

LXR

:   liver X receptor

LDL

:   low density lipoprotein

NAG

:   n-acetyl-beta-D-glucosaminidase

eNOS

:   endothelial nitric oxide synthase

nNOS

:   constitutive nitric oxide synthase

tNOS

:   total nitric oxide synthase

MAPK

:   mitogen-Activated Protein Kinase

mALB

:   microalbuminuria

MDA

:   malondialdehyde

MMP

:   matrix metalloproteinase

MCP

:   monocyte chemotactic protein

OLETF

:   otsuka Long-Evans Tokushima Fatty

PPAR

:   peroxisome proliferator-activated receptor

PAI

:   plasminogen activator inhibitor

PK1

:   protein kinase 1

PGF

:   prostaglandin F

ROS

:   reactive oxidative species

RAGE

:   receptor of advanced glycation end-products

SGK

:   serum and glucocorticoid induced protein kinase

STZ

:   streptozotocin

SOD

:   superoxide dismutase

α-SMA

:   α-smooth muscle actin

SCr

:   serum creatinine clearance rate

TGF

:   transforming growth factor

CM

:   chinese medicine

TARS

:   thiobarbituric acid reactive substances

TIMP

:   tissue inhibitor of metalloproteinase

TG

:   triglyceride

TC

:   total cholesterol

TSP-1

:   thrombospondin-1

TXB(2)

:   thromboxane B 2

UCr

:   urinary creatinine

β (2)-MG

:   urine β (2)-microglobin

UCP

:   uncoupling protein

UAlb

:   urinary microalbumin

UPR

:   unfolded protein response

UAE

:   urinary albumin excretion

VEGF

:   vascular endothelial growth factor
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